A collaborative project between non-animal testing laboratory, XCellR8, and dermatological testing organisation, Cutest, has been launched, thanks to a substantial grant by Innovate UK.
The aim of the project is to take the first steps to establishing reliable correlations between in vitro and in vivo predicative irritation testing, to eliminate the need to refer to historical and often unreliable animal test data. This project is an exciting opportunity to develop innovative methods to provide enhanced consumer protection through being able to predict potential irritancy from topically applied ingredients and products.
An important part of the application to Innovate UK was the support expressed by several leading personal care brands and retailers to the objective of developing new predictive safety testing methodologies that further remove the need to refer to historical animal testing. The 2-year research programme started on 1st August and is seeking to determine the correlation between human in vitro and in vivo data, using a panel of carefully selected reference materials to improve the sensitivity and predictive capacity of skin irritation tests.
Stewart Long, CEO of Cutest Systems said: “We are very excited to be awarded this significant research grant from Innovate UK to undertake this important work. We feel that the 30 years of in vivo irritation testing and published research by Cutest, combined with the state of the art in vitro testing and research that XCellR8 undertakes, makes this a powerful research collaboration with two leading and complementary companies.”
Dr Carol Treasure, Founder and Managing Director of XCellR8, added: “The latest funding from Innovate UK means we can continue to expand our research and development capabilities, which puts us at the leading edge of developing new, non-animal testing methods for the cosmetics industry, essential in complying with the EU Cosmetics Regulation. Many of our clients have expressed frustration with the unreliability of existing animal test data and its lack of relevance for humans. This grant will allow companies to take a leap forward in accurately establishing how ingredients may or may not irritate the skin prior to human volunteer trials, thus speeding up the process of bringing products to market.”